<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018419</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-014-TACT-MBC</org_study_id>
    <nct_id>NCT02018419</nct_id>
  </id_info>
  <brief_title>Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients</brief_title>
  <acronym>MBC</acronym>
  <official_title>In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess Safety of AllostimTM in Combination With Cryoablation in Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovative Therapies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunovative Therapies, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II study is designed to compare different treatment schedules of a personalized&#xD;
      anti-cancer vaccine protocol which combines the cryoablation of a selected metastatic lesion&#xD;
      with intra-tumor immunotherapy. The cryoablation causes the tumor to release tumor-specific&#xD;
      antigens into the surrounding environment. The injection of bioengineered allogeneic immune&#xD;
      cells, AlloStim(TM), into the lesion is designed to modulate the immune response and educate&#xD;
      the immune system to kill other tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will assess three different dosing schedules. A standard 3 plus 3 study design will&#xD;
      be used. The starting dose for each dosing schedule will be escalated in subsequent groups of&#xD;
      patients. The study will evaluate safety of increased frequency of AlloStim (TM) dosing and&#xD;
      anti-tumor effect of the new proposed dose and frequency schedule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    changing indication from breast cancer to metastatic colorectal cancer&#xD;
  </why_stopped>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of increased frequency of dosing</measure>
    <time_frame>Window is defined as the time required receiving two doses of AlloStim IV push plus 28 days follow-up</time_frame>
    <description>Three patients are enrolled at each frequency schedule in the absence of dose limiting toxicity (DLT). A DLT is defined as any allergic or autoimmune toxicity or other study drug related toxicity Grade 3 or higher during the DLT assessment window.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life</measure>
    <time_frame>From enrollment to 90 days after last dose administration.</time_frame>
    <description>Health-Related Quality of life will be measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and its supplementary breast cancer questionnaire (QLQ-BR23).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the anti-tumor effect of Allostim combined with cryoablation at the new proposed dose and frequency schedule.</measure>
    <time_frame>90 days after last dose administration</time_frame>
    <description>Each treatment schedule will be monitored for radiological, pathological, and immunological response. These assessments will be compared between three treatment schedules.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunological Response</measure>
    <time_frame>90 days after last dose administration</time_frame>
    <description>Blood samples will be evaluated for immunological response and a determination made as to whether immunological response correlates with RECIST and pathology.</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-Tumor Response</measure>
    <time_frame>90 days after last dose administration</time_frame>
    <description>The changes in tumor burden by RECIST and compare these changes with the pathological analysis of corresponding biopsies.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dosing Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the priming step with ID injection of AlloStim on Days 0, 7, and 14;&#xD;
the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;&#xD;
the activation step with an IV infusion of AlloStim on Day 28;&#xD;
the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;&#xD;
Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;&#xD;
the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;&#xD;
the activation step with an IV infusion of AlloStim on Day 21;&#xD;
the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.&#xD;
Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Schedule C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;&#xD;
the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;&#xD;
the activation step with an IV infusion of AlloStim on Day 21;&#xD;
the booster step with intravenous infusion of AlloStim on days 49 and 77.&#xD;
Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.</description>
    <arm_group_label>Dosing Schedule A</arm_group_label>
    <arm_group_label>Dosing Schedule B</arm_group_label>
    <arm_group_label>Dosing Schedule C</arm_group_label>
    <other_name>InSituVax</other_name>
    <other_name>Personalized anti-tumor vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.</description>
    <arm_group_label>Dosing Schedule A</arm_group_label>
    <arm_group_label>Dosing Schedule B</arm_group_label>
    <arm_group_label>Dosing Schedule C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women w/ histologically/cytologically confirmed breast carcinoma&#xD;
&#xD;
          2. Documented progressive metastatic disease not amenable to curative&#xD;
             surgery/radiotherapy&#xD;
&#xD;
          3. Age ≥18 and ≤70 years&#xD;
&#xD;
          4. Prior treatments that included capecitabine and both an anthracycline and a taxane&#xD;
             drug and resistant to taxane therapy&#xD;
&#xD;
               1. ER+ patients: minimum cumulative dose of anthracycline (≥ 180 mg/m² of&#xD;
                  doxorubicin or ≥ 300 mg/m² of epirubicin) or resistance to anthracycline,&#xD;
                  capecitabine and anti-hormonal therapy&#xD;
&#xD;
               2. Resistance is defined as tumor progression while receiving treatment or&#xD;
                  progression within 4 months of the last dose in the metastatic setting, or&#xD;
                  recurrence within 12 months in the neoadjuvant/adjuvant setting&#xD;
&#xD;
          5. Post-menopausal ER+ and/or PR+ must have received at least 2 lines of prior&#xD;
             anti-estrogen therapy, which includes an aromatase inhibitor&#xD;
&#xD;
          6. Her2+ patients: at least 1 Her2+ targeted regimen containing trastuzumab alone or with&#xD;
             pertuzumab/lapatinib. Trastuzumab/pertuzumab must have been discontinued at least 4&#xD;
             weeks before treatment&#xD;
&#xD;
          7. Prior radiation therapy completed &gt;4 weeks before treatment&#xD;
&#xD;
          8. Measurable disease according to revised RECIST v.1.1 guidelines with at least 1 lesion&#xD;
             deemed to be safely accessible for serial biopsy&#xD;
&#xD;
          9. ECOG &lt;2&#xD;
&#xD;
         10. Adequate hematological function&#xD;
&#xD;
               1. Absolute granulocyte count ≥ 1,500/mm3&#xD;
&#xD;
               2. Platelet count ≥ 100,000/mm3&#xD;
&#xD;
               3. PT/INR ≤ 1.5&#xD;
&#xD;
               4. INR correctable to ≤ 1.5 or a PT/PTT correctable to normal limits. Patients&#xD;
                  receiving anti-coagulation treatment with agent such as warfarin/heparin may&#xD;
                  participate. For patients on warfarin, INR should be monitored weekly prior to&#xD;
                  any intervention to assure INR is stable. Heparin/warfarin must be withheld&#xD;
                  before biopsy&#xD;
&#xD;
               5. Hemoglobin ≥ 9 g/dL (may be corrected by transfusion)&#xD;
&#xD;
         11. Adequate organ function&#xD;
&#xD;
               1. Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
               3. Alkaline phosphatase≤2.5 times ULN (≤5 times normal if liver involvement)&#xD;
&#xD;
               4. Aspartate aminotransferase (AST/SGOT) ≤ 5.0 times ULN&#xD;
&#xD;
               5. Alanine aminotransferase (ALT/SGPT) ≤ 5.0 times ULN&#xD;
&#xD;
         12. EKG without clinically relevant abnormalities&#xD;
&#xD;
         13. Pre-menopausal with child bearing potential subjects must use adequate contraception&#xD;
&#xD;
         14. Informed consent in the native language of the subject&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Peritoneal carcinomatosis&#xD;
&#xD;
          2. Moderate-large ascites accumulation requiring/likely to require paracentesis&#xD;
&#xD;
          3. Clinical/radiological evidence of brain metastasis/leptomeningeal involvement&#xD;
&#xD;
          4. Pulmonary lymphangitis/symptomatic pleural effusion (grade ≥ 2) that results in&#xD;
             pulmonary dysfunction requiring active treatment&#xD;
&#xD;
          5. History of 2nd primary malignancy, except: bilateral breast carcinoma, in situ&#xD;
             carcinoma of the cervix, adequately treated non-melanomatous carcinoma of the skin,&#xD;
             and other malignancy treated at least 5 years with no evidence of recurrence&#xD;
&#xD;
          6. &gt;3 prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
          7. History of severe hypersensitivity to monoclonal antibody drugs/any contraindication&#xD;
             to study drugs&#xD;
&#xD;
          8. Pregnant or breast feeding&#xD;
&#xD;
          9. Any serious, concurrent uncontrolled medical disorder&#xD;
&#xD;
         10. Prior hepatectomy, liver chemoembolization, liver cryoablation/ radiofrequency ablated&#xD;
&#xD;
         11. Symptomatic pulmonary disease&#xD;
&#xD;
         12. Bevacizumab (Avastin®) within 3 weeks of accrual&#xD;
&#xD;
         13. Prior allogeneic bone marrow/stem cell or solid organ transplant&#xD;
&#xD;
         14. Chronic use (&gt; 2 weeks) of greater than physiologic doses of corticosteroid agent&#xD;
             (dose equivalent to &gt; 10 mg/day of prednisone) within 30 days of the first day of&#xD;
             study treatment. Topical and inhaled corticosteroids are permitted&#xD;
&#xD;
         15. Concomitant active autoimmune disease&#xD;
&#xD;
         16. Prior experimental therapy/cancer vaccine treatment&#xD;
&#xD;
         17. Current immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or&#xD;
             tacrolimus within 1 month of study entry&#xD;
&#xD;
         18. History of blood transfusion reactions&#xD;
&#xD;
         19. Known allergy to bovine products&#xD;
&#xD;
         20. Know allergy to murine products&#xD;
&#xD;
         21. Progressive viral/bacterial infection. All infections must be resolved and the patient&#xD;
             must remain afebrile for 7days without antibiotics prior to enrollment&#xD;
&#xD;
         22. Cardiac disease of symptomatic nature or cardiac ejection fraction &lt; 45%&#xD;
&#xD;
         23. History of HIV positivity or AIDS&#xD;
&#xD;
         24. Psychiatric/addictive disorders or other condition that, in the opinion of the&#xD;
             investigator, would preclude study participation&#xD;
&#xD;
         25. Concurrent medication known to interfere with platelet function or coagulation (e.g.,&#xD;
             aspirin, ibuprofen, clopidogrel, or warfarin) unless can be discontinued for an&#xD;
             appropriate time period based on the drug half-life and known activity (e.g., aspirin&#xD;
             for 7 days) prior to cryoablation procedure&#xD;
&#xD;
         26. Use of low molecular weight heparin preparations unless can be discontinued 8 hours&#xD;
             prior to cryoablation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zivile Katiliene, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Immunovative Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Oncology Associates of San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3.</citation>
    <PMID>18054441</PMID>
  </results_reference>
  <results_reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Slavin S. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.</citation>
    <PMID>18565579</PMID>
  </results_reference>
  <results_reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.</citation>
    <PMID>18834631</PMID>
  </results_reference>
  <results_reference>
    <citation>Janikashvili N, LaCasse CJ, Larmonier C, Trad M, Herrell A, Bustamante S, Bonnotte B, Har-Noy M, Larmonier N, Katsanis E. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood. 2011 Feb 3;117(5):1555-64. doi: 10.1182/blood-2010-06-288621. Epub 2010 Dec 1.</citation>
    <PMID>21123824</PMID>
  </results_reference>
  <results_reference>
    <citation>LaCasse CJ, Janikashvili N, Larmonier CB, Alizadeh D, Hanke N, Kartchner J, Situ E, Centuori S, Har-Noy M, Bonnotte B, Katsanis E, Larmonier N. Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism. J Immunol. 2011 Dec 15;187(12):6310-7. doi: 10.4049/jimmunol.1101812. Epub 2011 Nov 9.</citation>
    <PMID>22075702</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

